Here, we show that combined targeting of mevalonate pathway and PRC2 dependency convey significant survival benefit in aggressive mouse models of mesothelioma, and thus this combination might be a more viable option for treating BAP1-deficient mesothelioma. This evidence concerns the gene BAP1 and mesothelioma.